Sovenyr reads 17 million signals across research, patents, clinical trials, regulators and markets — and flags where independent sources converge, often months before the headline. One data dispatch a week, in plain English.
Your early-access invitation will come from sovenyr.com. Until then, the weekly dispatch does the talking.
The world doesn't move in one channel — it moves across all of them at once. Sovenyr watches the whole board and reads the seams between the layers.
One archive spanning science, patents, clinical trials, regulators, corporate filings and markets — 30 years deep, ~76 live sources. Not a headline aggregator; the raw cross-section.
The signal that precedes a story is independent sources starting to point the same way — a research surge meeting a trials surge meeting a filing. Sovenyr detects that alignment while it's still early and scores its lead time.
Every external figure is checked against independent references before it reaches you. Single-source claims never become headlines. Real numbers, cited, no hype.
And the pipeline moves months earlier. Two dispatches, read straight from the cross-source signal graph.
| Dispatch | Signals | Pipeline read |
|---|---|---|
Therapeutics The metabolic supercycle has a second act |
1,023 | 501 trials · 495 papers next wave: oral + triple-agonists |
AI & Medicine AI hasn't reached the clinic yet |
110 | ~100 upstream · 0 trials · 0 FDA |
A cross-section, not a silo — research through markets, backfilled 30 years and collected continuously.
A Bloomberg terminal costs $24,000 a year. The instinct it sells — seeing the shift before everyone else — shouldn't. Sovenyr is that instinct, for the rest of us.
We're opening it to a first group of readers who want to go past the dispatch, into the data itself. Leave your name — invitations go out in waves.
One invitation, when it's your turn. No spam, no noise.